S&P 500 cuts losses as Nvidia climbs ahead of results
On Tuesday, H.C. Wainwright reaffirmed its Buy rating and $120.00 price target for Cytokinetics stock (NASDAQ:CYTK), representing a significant upside from the current price of $44.91. With a market capitalization of $5.3 billion, InvestingPro analysis suggests the stock is currently overvalued based on its proprietary Fair Value model. The endorsement follows the company’s recent announcement of new analyses concerning aficamten’s effects when used with standard of care (SoC) combination therapy, as well as its long-term impact on cardiac structure and function. These findings are slated for presentation at the Annual American College of Cardiology Scientific Session & Expo 2025 ( ACC (NSE:ACC).25), which will take place at the end of March.
Cytokinetics shared the new information on Monday, detailing the additional benefits of aficamten, a drug designed for the treatment of hypertrophic cardiomyopathy (HCM). These results add to prior data which suggested aficamten’s potential for cardiac remodeling. The data previously presented at various scientific meetings throughout 2024 reinforced the drug’s profile and supported the company’s plans for a New Drug Application (NDA) submission.
The upcoming presentations at ACC.25 are expected to include two key points. Firstly, the combination of aficamten with disopyramide does not improve the clinical efficacy beyond aficamten alone, and discontinuing disopyramide does not affect the efficacy of the cardiac myosin inhibitor (CMI). Secondly, extended treatment with aficamten, ranging from 48 to 72 weeks, has shown positive effects on heart structure, including reduced left ventricular mass and left atrial size, no progression of replacement myocardial fibrosis, and a decrease in interstitial fibrosis.
These findings are significant as they suggest that aficamten can be effective as a monotherapy and offer long-term benefits for cardiac structure without the need for additional medications like disopyramide. The clinical trials for aficamten allowed for the inclusion of symptomatic obstructive HCM (oHCM) patients who were already receiving disopyramide but continued to experience left ventricular outflow tract (LVOT) obstruction. According to InvestingPro data, Cytokinetics maintains strong liquidity with a current ratio of 6.17, though the company reported a significant EBITDA loss of $526.7 million in the last twelve months. Discover 6 more exclusive InvestingPro Tips and comprehensive financial analysis in our detailed Pro Research Report.
H.C. Wainwright’s reiterated Buy rating and price target reflect a continued positive outlook for Cytokinetics’ aficamten based on the accumulating evidence of its efficacy and safety profile in the treatment of HCM. The firm’s analysts highlight the importance of the upcoming ACC.25 presentations as an opportunity to further solidify aficamten’s therapeutic potential. The company’s strong analyst consensus rating of 1.67 (where 1 is Strong Buy) suggests broad market confidence, with price targets ranging from $47 to $120. The next earnings report is expected on May 1, 2025, where investors will be watching for progress on the company’s revenue growth, which showed a remarkable 145% increase in the last twelve months despite ongoing profitability challenges.
In other recent news, Cytokinetics reported a notable increase in revenue for the fourth quarter of 2024, reaching $16.9 million compared to $1.7 million in the same period last year. Despite a slight miss in earnings per share, the company’s financial guidance for 2025 indicates operating expenses between $670 million and $710 million. The company is also preparing for a potential U.S. commercial launch of aficamten in September 2025, pending FDA approval. Morgan Stanley (NYSE:MS) recently upgraded Cytokinetics to an Overweight rating, setting a price target of $67, while Citi reiterated a Buy rating with an $86 target. Cytokinetics is advancing its regulatory interactions with the FDA, with a mid-cycle meeting expected in March and a PDUFA date set for September 26, 2025. The company has also submitted a 120-day safety update for aficamten and is anticipating the release of MAPLE-HCM study data in the second quarter of 2025. These developments highlight Cytokinetics’ strategic focus on expanding its market presence and advancing its pipeline in the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.